Abstract:Background: Sickle cell disease (SCD) is associated with chronic hemolytic anemia and a heightened inflammatory state. Multiple inflammatory pathways have been shown to be activated in SCD, however the causal role of these pathways in mediating organ damage and contributing to stroke is unclear. Methods: Bone marrow transplantation (bmt) from SCD (Townes) to wild-type (WT) recipient mice was used to generate SCD mice (WTSCD). To generate mice with non-hematopoietic deficiency of the interleukin-1 receptor (IL1R), SCD marrow was transplanted into IL1R deficient recipients (IL1R-/- SCD). Other WTSCD mice were given the IL1R inhibitor, anakinra, or PBS for 2 or 4 weeks before sacrifice. Iron and collagen staining were performed in multiple formalin-fixed tissues with Prussian blue and Masson's Trichrome, respectively. Complete blood counts and reticulocyte percentages were analyzed 15 weeks following BMT. Plasma levels of soluble E-selectin (sE-sel) and soluble P-selectin (sP-sel) were measured 14 weeks following bmt with ELISA. Ischemic stroke was induced by middle cerebral artery (MCA) photothrombosis at 16 weeks of age. WTSCD mice were given anakinra following stroke induction. Seventy-two hours after MCA occlusion, stroke volume was assessed by staining brain sections with 2, 3, 5-triphenyltetrazolium chloride. Formalin-fixed brain sections were also stained for macrophages. Results: All SCD mice were anemic and the severity of anemia was not different between WTSCD and IL1R-/- SCD mice. Increased circulating erythrocytes (9.01 ± 0.78 vs 6.77 ± 0.18 M/uL; p<0.05) and decreased reticulocytes (25.31 ± 1.79 vs 32.45 ± 2.74%; p<0.05) were observed in WTSCD mice treated with anakinra for 4 weeks. Two week anakinra treatment was sufficient to decrease organ iron deposition and lung collagen deposition. In vivo treatment with anakinra also decreased erythrocyte sickling in a whole blood ex vivo sickling assay (15.14 ± 0.94 vs 24.18 ± 1.95 % sickled; p<0.01). Further, in vitro treatment of WTSCD whole blood with IL-1β increased sickling (26.70 ± 0.39 vs 22.34 ± 0.95; p<0.05), and this was ameliorated with in vitro pretreatment with anakinra. Alterations to ex vivo sickling were not observed when conditions were repeated on erythrocytes alone. Stroke volume was significantly reduced in IL1R-/- SCD mice compared to WTSCD mice 3 days following MCA occlusion (8.08 ± 0.91 vs 11.10 ± 1.16 % hemisphere; p<0.05). Post-stroke treatment of WTSCD mice with anakinra also decreased stroke size compared to vehicle-treated mice (14.45 ± 1.44 vs 9.7 ± 3.23 % hemisphere; p=0.05). Non-hematopoietic deficiency of IL1R decreased sE-sel (vs 50.10 ± 2.31 vs 32.12 ± 2.08 pg/mL; p<0.05) and sP-sel (155.98 ± 24.44 vs 327.23 ± 18.31 ng/mL; p<0.05) levels in post-stroke animals and decreased the number of macrophages observed in the peri-stroke area (0.26 ± 0.05 vs 0.722 ± 0.15 % hemisphere; p<0.05). Conclusions: Deficiency of non-hematopoietic IL1R or treatment with an IL1R antagonist was appears beneficial towards several phenotypes in a mouse model of SCD. Given the safety of IL1R inhibitors in various patient populations, this study reveals a potential therapeutic intervention for treatment of sickle cell patients. Disclosures No relevant conflicts of interest to declare.

Hemolysis impairs sickle cell erythropoiesis

Heme-regulated Eif2alpha Kinase (HRI) is Required for Translational Regulation and Survival of Erythroid Precursors in Iron Deficiency

Spleen tyrosine kinase inhibition mitigates hemin-induced thromboinflammation in the lung and kidney of sickle cell mice

Antiviral response and HIV-1 inhibition in sickle cell disease

Products of red blood cell degradation inhibit responsiveness of the erythropoietin oxygen sensor

Interleukin‐1 Receptor Antagonism Leads to Improved Anaemia in a Murine Model of Sickle Cell Disease and is Associated with Reduced Ex Vivo Platelet‐mediated Erythrocyte Sickling

Heme Induces IL-6 and Cardiac Hypertrophy Genes Transcripts in Sickle Cell Mice

Paradoxical Protection from Atherosclerosis and Thrombosis in A Mouse Model of Sickle Cell Disease

Effects of Targeting the Interleukin-1 Receptor in a Murine Model of Sickle Cell Disease

Non-hematopoietic Deficiency of Proprotein Convertase Subtilisin/kexin Type 9 Deficiency Leads to More Severe Anemia in a Murine Model of Sickle Cell Disease.

Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice

Amiodarone Improves Anemia in a Murine Model of Sickle Cell Disease and is Associated with Increased Erythrocyte Bis(monoacylglycerol) Phosphate.

Interferon-sensitized hematopoietic progenitors dynamically alter organismal immunity

Bacterial Lipopolysaccharides Suppress Erythroblastic Islands and Erythropoiesis in the Bone Marrow in an Extrinsic and G- CSF-, IL-1-, and TNF-Independent Manner

COping with acute sickle cell hemolysis

Elevated Sphingosine-1-phosphate Promotes Sickling and Sickle Cell Disease Progression

The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation.

Transcriptomic profiling of an ex vivo model of erythropoiesis uncovers potential genes and pathways involved into the pathogenesis of sickle cell disease

Heme Causes Pain in Sickle Mice via Toll-Like Receptor 4-Mediated Reactive Oxygen Species- and Endoplasmic Reticulum Stress-Induced Glial Activation

Impaired Erythrocyte Deformability in Transgenic Ho-1g143h Mutant Mice

Heme- and iron-activated macrophages in sickle cell disease: an updated perspective